Magnitude Biosciences 🇬🇧
Magnitude Biosciences provides customized C. elegans studies using automated imaging for drug discovery, ageing, and toxicity research.
About Magnitude Biosciences
Magnitude Biosciences specializes in contract lab services utilizing C. elegans for high-throughput screening and customized studies across various research areas, including aging, neurodegeneration, and toxicity. Their technologies include the VivoScan™ platform for whole-organism screening and automated imaging to efficiently assess health outcomes and compound efficacy.
Magnitude Biosciences is a UK-based company founded in 2018, now around 19 people. It has raised $3.8M in disclosed funding. FundFinder classes it as Health & Bio.
Founded by Craig Manning (Co-Founder/Director; previously SETsquared Partnership; University of York), Boo Virk (Founder; Durham University).
Its investors also appear on FundFinder's most-active lists for Seed · Generalist (110 funds), Seed · Healthcare & Wellbeing (87 funds), Seed · Climate & Sustainability (80 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Seed · Sep 2026
Northstar Ventures- Northstar Ventures — Northstar Ventures is an early stage VC, working with mission-based founders trying to solve solve societal challenges. · cheques £150k – £700k